These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16163398)

  • 1. Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.
    Forchetti CM
    Prim Care Companion J Clin Psychiatry; 2005; 7(4):155-61. PubMed ID: 16163398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence.
    Riverol M; Slachevsky A; López OL
    Eur Neurol J; 2011 Jul; 3(1):15-19. PubMed ID: 25302109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil.
    Kano O; Ito H; Takazawa T; Kawase Y; Murata K; Iwamoto K; Nagaoka T; Hirayama T; Miura K; Nagata R; Kiyozuka T; Aoyagi J; Sato R; Eguchi T; Ikeda K; Iwasaki Y
    Neuropsychiatr Dis Treat; 2013; 9():259-65. PubMed ID: 23431041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy.
    Atri A; Molinuevo JL; Lemming O; Wirth Y; Pulte I; Wilkinson D
    Alzheimers Res Ther; 2013; 5(1):6. PubMed ID: 23336974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.
    Schmitt FA; Wichems CH
    Prim Care Companion J Clin Psychiatry; 2006; 8(3):158-9. PubMed ID: 16912819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
    Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
    J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R; Adityanjee ; Dysken M
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease.
    Li DD; Zhang YH; Zhang W; Zhao P
    Front Neurosci; 2019; 13():472. PubMed ID: 31156366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donepezil in more advanced Alzheimer's disease.
    Rawls WN
    Consult Pharm; 2005 Jul; 20(7):592-600. PubMed ID: 16548656
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.